No title
Particulate matter formation in parenteral protein formulations poses significant safety risks and quality challenges. In the multi-dose injectable products, therapeutic proteins, surfactants, and antimicrobial preservatives are present together, forming a complex system that is more prone to destabilizing interactions. Cyclodextrin (CD) has been proposed as a potential stabilizer, yet its role in
